Replies to post #305194 on NorthWest Biotherapeutics Inc (NWBO)

[abeta]

~ 96 Percent of High-Risk Melanoma Patients Were Alive Three Years After Completing the Vaccine Series Compared to 77 Percent of those Treated with Placebo

~~ 52 Percent of Patients Treated with the Vaccine Were Disease-Free at Three Years Compared to 27 Percent in the Placebo Arm

~~ New Analysis Reveals Optimized Vaccine Formulation Results in Improved Clinical Outcomes

~~ Treatment with Vaccine in Combination with Checkpoint Inhibitors Doubled Disease-Free Survival Rate Compared to Checkpoint Inhibitors Alone ~

Aug 05, 2020, 07:15 ET

Elios Therapeutics Personalized Cancer Vaccine Demonstrates Long-Term Survival Benefit Among High-Risk Melanoma Patients in Phase IIb Final Analysis
https://www.prnewswire.com/news-releases/elios-therapeutics-personalized-cancer-vaccine-demonstrates-long-term-survival-benefit-among-high-risk-melanoma-patients-in-phase-iib-final-analysis-301106313.html

use of its personalized tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine in patients with Stage III or Stage IV melanoma at high risk of recurrence following complete surgical resection.

"We now have long-term data demonstrating that use of the TLPLDC vaccine for the adjuvant treatment of high-risk melanoma correlates with a 93 percent increase in patients alive at three years without their disease returning. This trial also significantly improves our understanding of the optimal method of vaccine production," said Buddy Long, chief executive officer of Elios Therapeutics. "These new data, combined with the doubled rate of disease-free survival among patients treated with the vaccine and standard of care checkpoint inhibitors, further strengthen our confidence that the personalized TLPLDC vaccine provides a clinically meaningful benefit for people with high-risk melanoma. We look forward to advancing this vaccine with a registrational Phase III trial that will move us one step closer to bringing this important treatment to patients as soon as possible."

The TLPLDC vaccine is a personalized treatment that is created using a patient's own blood and tumor cells. Samples are collected at resection, frozen, and sent to the lab where they are used to create autologous tumor lysate, which is loaded into yeast cell wall particles. This combination is then introduced to the patient's dendritic cells, leading to the creation of the final TLPLDC vaccine. The time from resection to injection of the vaccine takes approximately three weeks.